PsyPost
No Result
View All Result
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology

Response to common schizophrenia, bipolar treatment drug is dictated by gene type

by Columbia University Medical Center
September 14, 2016
in Psychopharmacology
Photo credit: DigitalGenetics/Fotolia

Photo credit: DigitalGenetics/Fotolia

Share on FacebookShare on Twitter

A drug prescribed to many patients with schizophrenia or bipolar disorder may decrease negative symptoms for people with a certain variant of the COMT gene, suggests a new study from researchers at Columbia University Medical Center (CUMC).

The drug—a mood stabilizer called valproate—is commonly prescribed to treat bipolar disorder and schizophrenia, though its mechanism of action is poorly understood and only some patients respond to the treatment. Few options currently exist for treating the debilitating “negative” symptoms of severe psychiatric disorders, which include slowed movement, blunted affect, and social withdrawal. (Antipsychotic medications are used to treat hallucinations, delusions, and other “positive” symptoms of schizophrenia).

The authors conclude that valproate may be effective for treating negative symptoms in psychiatric patients with two copies of the “Val” variant of the COMT gene, which breaks down dopamine in the brain. In the roughly 40 percent of patients with this genotype, higher levels of proline (a neuromodulator that is increased by valproate), correlated with fewer negative symptoms. In patients who have a “Met” variant of COMT, rising levels of proline appeared to do the exact opposite: these patients had more or worse negative symptoms, and the symptoms did not improve with valproate.

The results were published on September 13 in Translational Psychiatry by Catherine Clelland, PhD, assistant professor of pathology and cell biology (in the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain) at Columbia University Medical Center and colleagues at Columbia, the Nathan S. Kline Institute, and NYU School of Medicine.

Previous studies have demonstrated an interaction between elevated blood levels of proline—a modulator of neurotransmitters that, in higher amounts, is associated with psychiatric illnesses including schizophrenia—and a gene called COMT, which makes an enzyme that helps maintain normal levels of neurotransmitters in the brain. One version of the enzyme contains the amino acid methionine (Met), while another type contains valine (Val). People may inherit one copy of each type (Val/Met) or two copies of the type (Val/Val or Met/Met). Additional studies have suggested that COMT Val/Val has greater enzymatic activity, increasing its ability to lower dopamine levels in the brain.

In this study, the researchers compared the severity of negative symptoms and proline levels in 95 hospitalized schizophrenia patients with variants of the COMT gene. In patients with COMT Val/Val, symptom severity decreased as proline levels rose. In contrast, higher proline levels were associated with greater negative symptom severity in patients with the Met/Met gene.

Among those patients who were being treated with valproate (approximately one-third of the schizophrenia patients), negative symptoms were more severe in those with the Met/Met gene than in those with the Val/Val gene.

The researchers also evaluated negative symptoms in 43 patients with bipolar disorder, about half of whom were treated with valproate. After one week of treatment, negative symptoms decreased for those with the Val/Val genotype, while symptoms increased or remained the same for those with the Met/Met genotype.

“While longitudinal studies are needed to confirm our results, this study suggests that boosting proline levels in patients with the Val/Val gene may help address negative symptoms, whereas increasing proline in patients with the Met/Met gene may have the opposite effect,” said Dr. Clelland. “This information may help to determine which patients may be most likely to benefit from treatment with mood stabilizers such as valproate that are known to modulate proline levels.”

ShareTweetSendScanShareSharePinSend

Get all the latest updates on new psychology research with the free PsyPost app.
 


NEWSLETTER SIGN-UP

STAY CONNECTED

TRENDING

New study suggests that psychopathic individuals tend to become even worse after age 50

People with borderline tendencies have a higher number of estranged relationships

Biden voters were much more likely to report negative voting than Trump voters in the 2020 election

Women withhold honest sexual communication to protect their partner’s perceived masculinity, study finds

Partners’ heart rates synchronize in complex patterns of interaction when they are in close proximity

Psychopathic women who desire marriage are more likely to experience insults from their partner

RECENT

Reality TV viewing is associated with increased support for traditional gender roles among adolescents

Men who pose shirtless on Tinder are perceived as less competent and more prone to risky sexual behavior

Social media helps improve mood among older adults by enriching their in-person encounters, study suggests

Biden voters were much more likely to report negative voting than Trump voters in the 2020 election

Women withhold honest sexual communication to protect their partner’s perceived masculinity, study finds

  • Cognitive Science
  • COVID-19
  • Mental Health
  • Social Psychology
  • Drug Research
  • Conspiracy Theories
  • Meditation
  • Psychology of Religion
  • Aviation Psychology and Human Factors
  • Relationships and Sexual Health
Powered by

About

PsyPost is a psychology and neuroscience news website dedicated to reporting the latest research on human behavior, cognition, and society. (READ MORE...)

  • Contact us
  • Privacy policy

No Result
View All Result
  • About
    • Newsletter signup form
  • Cart
  • Checkout
  • Contact
  • Contact us
  • My account
  • Privacy policy
  • Psychology news
  • PsyPost app privacy policy
  • Shop
  • SmartMag Home

This website uses cookies. By continuing to use this website you are giving consent to cookies being used.